RhumbLine Advisers’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-185,945
| Closed | -$65K | – | 2901 |
|
|
2016
Q3 | $65K | Buy |
185,945
+6,450
| +4% | +$2.25K | ﹤0.01% | 2845 |
|
|
2016
Q2 | $84K | Buy |
179,495
+17,275
| +11% | +$8.08K | ﹤0.01% | 2935 |
|
|
2016
Q1 | $221K | Buy |
162,220
+1,375
| +0.9% | +$1.87K | ﹤0.01% | 2692 |
|
|
2015
Q4 | $236K | Buy |
160,845
+14,850
| +10% | +$21.8K | ﹤0.01% | 2710 |
|
|
2015
Q3 | $231K | Buy |
145,995
+5,395
| +4% | +$8.54K | ﹤0.01% | 2705 |
|
|
2015
Q2 | $239K | Buy |
140,600
+16,015
| +13% | +$27.2K | ﹤0.01% | 2787 |
|
|
2015
Q1 | $173K | Buy |
124,585
+22,300
| +22% | +$31K | ﹤0.01% | 2867 |
|
|
2014
Q4 | $154K | Buy |
102,285
+2,875
| +3% | +$4.33K | ﹤0.01% | 2882 |
|
|
2014
Q3 | $205K | Sell |
99,410
-2,100
| -2% | -$4.33K | ﹤0.01% | 2742 |
|
|
2014
Q2 | $311K | Buy |
101,510
+15,609
| +18% | +$47.8K | ﹤0.01% | 2583 |
|
|
2014
Q1 | $215K | Sell |
85,901
-4,070
| -5% | -$10.2K | ﹤0.01% | 2727 |
|
|
2013
Q4 | $446K | Buy |
89,971
+4,500
| +5% | +$22.3K | ﹤0.01% | 2326 |
|
|
2013
Q3 | $194K | Buy |
85,471
+9,461
| +12% | +$21.5K | ﹤0.01% | 2799 |
|
|
2013
Q2 | $169K | Buy |
+76,010
| New | +$169K | ﹤0.01% | 3069 |
|
RhumbLine Advisers's RXII Position: Q4 2016 in Review
RhumbLine Advisers sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 185,945 shares — an estimated $65K sold.
RhumbLine Advisers first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $446K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- RhumbLine Advisers reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- RhumbLine Advisers sold 185,945 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $65K.
- RhumbLine Advisers first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- RhumbLine Advisers's GALENA BIOPHARMA INC COM position peaked at $446K in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on RhumbLine Advisers's 13F filing for Q4 2016, filed 27 Jan 2017.